B+
Bull case
20%
Probability
Target price
$176.00
+142.8% vs current
ABVX
AbivaxANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment AIMost likely
B
Base case
60%
Probability
Target price
$130.14
+79.5% vs current
B-
Bear case
20%
Probability
Target price
$101.00
+39.3% vs current
AI sentiment snapshot
Latest data as of 2026-01-17
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+100.0
Score
AI commentary
Analyst consensus centers near the base target (~$130) with highs approaching the mid-to-high $170s, implying meaningful upside from the anchor ($116.98) if trials and partnering progress. Market tone is cautiously optimistic but event-driven: near-term readouts and funding updates are the primary catalysts for re-rating.
RankAlpha Sentiment AI - 2026-01-17
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-04-17catalystLead clinical program Phase 2 readoutHigh impact
Assuming a near-term Phase 2 readout for Abivax's lead clinical program; date is estimated (company timing not explicit) and could materially move the stock on efficacy/safety news [#SERP-1].
2026-12-31event12-month consensus re-rating windowHigh impact
Analyst coverage and consensus price targets are likely to be updated within the next 12 months following clinical or commercial milestones; date uses the year-end window assumption [#SERP-2], pick window end.
2027-01-17catalystPartnership or licensing transaction for late-stage assetHigh impact
Commercial licensing or partnering for a late-stage program would validate value and accelerate adoption; timing is multi-quarter and treated as long-term potential [#SERP-5].
Recommendation
N/A
No formal recommendation provided.
As of 2026-01-17 • Updated nightlySource: Internal modelMethodology